NDAINJECTIONINJECTABLE
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
CARDIOGEN-82 (rubidium chloride rb-82) by Bracco is 82 is analogous to potassium ion (k) in its biochemical behavior and is extracted by the myocardium in proportion to the blood flow. First approved in 1989.
Drug data last refreshed 37m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDIOGEN-82 is a rubidium chloride Rb-82 radiopharmaceutical injectable used for myocardial perfusion imaging to assess cardiac blood flow and viability. Rb-82 mimics potassium behavior and is extracted by viable myocardium via Na/K-ATPase pumps, allowing differentiation of perfused versus infarcted tissue. The tracer concentrates in healthy heart tissue while clearing from necrotic areas, enabling non-invasive cardiac assessment.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), indicating consolidation of sales team and shift toward efficiency and retention-focused roles.
Mechanism of Action
82 is analogous to potassium ion (K) in its biochemical behavior and is extracted by the myocardium in proportion to the blood flow. Rb participates in the sodium-potassium (Na/K) ion exchange pumps that are present in cell membranes. The intracellular uptake of Rb 82 requires maintenance of ionic…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning at Two Clinical Sites
Started Sep 2011
72 enrolled
Radiation Exposure
Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning
Started Sep 2011
155 enrolled
Radiation Exposure
Why This Matters for Your Career
Worked on CARDIOGEN-82 at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.